Does lowering cholesterol reduce your dementia risk, or raise it?
A recent study is making waves in the media, with lipid experts claiming it definitively proves that statins reduce dementia risk. But here’s the problem: the study didn’t test statins; in fact, it didn’t involve any medications, and the authors explicitly stated that. So why is it being used to push a pharmaceutical narrative? And how does this align, or conflict, with other studies showing opposite outcomes, including increased Alzheimer’s risk with certain cholesterol-lowering mutations?
In this video, Dr. Bret Scher examines:
– What this latest study really measured (and what it didn’t)
– Why genetic mutations are not equivalent to the effects of drugs
– Why context matters: metabolic health, study design, and population differences
– The danger of confirmation bias in medical journalism
– Why metabolic health may be one of the most powerful factors influencing dementia risk
We know it’s frustrating not to have a clear, black-and-white answer. But when it comes to something as critical as brain health, it’s essential to avoid drawing false or oversimplified conclusions. Join us for a deeper, more thoughtful analysis that empowers informed decision-making.
👉 Learn more about the link between brain health and metabolism by subscribing to Metabolic Mind:
#MetabolicMind #FoodAsMedicine #Alzheimers #Statins
*Expert Featured:*
– Dr. Bret Scher
– Baszucki Group Medical Director
–
*Resources Mentioned:*
*Cholesterol-lowering drug targets reduce risk of dementia: Mendelian randomization and meta-analyses of 1 million individuals*
–
*Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease*
–
*High total cholesterol levels in late life associated with a reduced risk of dementia*
–
*Better memory functioning associated with higher total and LDL cholesterol levels in very elderly subjects without the APOE4 allele*
–
*Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis*
–
*The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study*
–
*Free CME Clinician Trainings:*
Are you a clinician who would like to learn more about the science behind these therapies and how to implement them in practice? Earn CME with our growing library of courses from some of the top experts in the field including Dr. Chris Palmer, Dr. Georgia Ede, Dr. Matthew Bernstein and Dr. Bret Scher with more coming soon.
Our courses have been made *FREE* by grants from Baszucki Group, so we can spread these powerful therapies as widely as possible. Earn CME/CNE credits:
Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.
Learn more about metabolic psychiatry and find helpful resources at
*About us:*
Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education, community, and hope to people struggling with mental health challenges and those who care for them.
Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications.
source